Cytochrome P450-derived eicosanoids in brain: From basic discovery to clinical translation.

Q1 Pharmacology, Toxicology and Pharmaceutics Advances in pharmacology Pub Date : 2023-01-01 DOI:10.1016/bs.apha.2022.11.002
Catherine M Davis, Aseel H Ibrahim, Nabil J Alkayed
{"title":"Cytochrome P450-derived eicosanoids in brain: From basic discovery to clinical translation.","authors":"Catherine M Davis,&nbsp;Aseel H Ibrahim,&nbsp;Nabil J Alkayed","doi":"10.1016/bs.apha.2022.11.002","DOIUrl":null,"url":null,"abstract":"<p><p>Cytochrome P450 metabolism of arachidonic acid produces epoxyeicosatrienoates (EETs) and hydroxyeicosatetraenoates (HETEs). Both classes of eicosanoids play important and opposing roles in brain function and disease. EETs promote vasodilation and exhibit antiinflammatory and cytoprotective properties; their biological action is blunted by metabolism to less active diols by the enzyme soluble epoxide hydrolase (sEH). EETs levels are dysregulated in disease states, primarily due to increased activity of sEH. Inhibition of sEH is a promising therapeutic approach for multiple brain disorders including stroke, dementia, subarachnoid hemorrhage and epilepsy. In this chapter, we summarize evidence implicating P450 eicosanoids and their synthetic and metabolizing enzymes in brain health and disease, and experimental and clinical studies targeting these pathways for brain disorders. We also discuss the diagnostic utility of quantifying P450 eicosanoids and their enzymes as disease biomarkers. Remarkable progress has been achieved in translating basic science discoveries in this field clinically.</p>","PeriodicalId":7366,"journal":{"name":"Advances in pharmacology","volume":"97 ","pages":"283-326"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in pharmacology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/bs.apha.2022.11.002","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0

Abstract

Cytochrome P450 metabolism of arachidonic acid produces epoxyeicosatrienoates (EETs) and hydroxyeicosatetraenoates (HETEs). Both classes of eicosanoids play important and opposing roles in brain function and disease. EETs promote vasodilation and exhibit antiinflammatory and cytoprotective properties; their biological action is blunted by metabolism to less active diols by the enzyme soluble epoxide hydrolase (sEH). EETs levels are dysregulated in disease states, primarily due to increased activity of sEH. Inhibition of sEH is a promising therapeutic approach for multiple brain disorders including stroke, dementia, subarachnoid hemorrhage and epilepsy. In this chapter, we summarize evidence implicating P450 eicosanoids and their synthetic and metabolizing enzymes in brain health and disease, and experimental and clinical studies targeting these pathways for brain disorders. We also discuss the diagnostic utility of quantifying P450 eicosanoids and their enzymes as disease biomarkers. Remarkable progress has been achieved in translating basic science discoveries in this field clinically.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
脑细胞色素p450衍生的类二十烷:从基础发现到临床转化。
花生四烯酸的细胞色素P450代谢产生环氧二十碳三烯酸酯(EETs)和羟基二十碳四烯酸酯(HETEs)。这两类类二十烷酸在脑功能和疾病中发挥着重要而相反的作用。EETs促进血管舒张,具有抗炎和细胞保护作用;它们的生物作用被酶溶环氧化物水解酶(sEH)代谢成活性较低的二醇而减弱。EETs水平在疾病状态下失调,主要是由于sEH活性增加。抑制sEH是一种很有前途的治疗多种脑部疾病的方法,包括中风、痴呆、蛛网膜下腔出血和癫痫。在本章中,我们总结了P450类二十烷酸及其合成和代谢酶与大脑健康和疾病有关的证据,以及针对这些途径治疗大脑疾病的实验和临床研究。我们还讨论了定量P450类二十烷酸及其酶作为疾病生物标志物的诊断效用。在将这一领域的基础科学发现转化为临床方面取得了显著进展。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Advances in pharmacology
Advances in pharmacology Pharmacology, Toxicology and Pharmaceutics-Pharmacology
CiteScore
9.10
自引率
0.00%
发文量
45
期刊最新文献
Drug discovery strategy for TAK-418, a specific inhibitor of LSD1 enzyme activity, as a novel therapy for autism. Evolution of D-amino acid oxidase inhibitors: From concept to clinic. Inhibition of brain glutamate carboxypeptidase II (GCPII) to enhance cognitive function. Modulatory and protective effects of prolyl hydroxylase domain inhibitors in the central nervous system. Neutral sphingomyelinase 2: A promising drug target for CNS disease.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1